Answers are grounded in this paper and cite their sources.
Introduction: Opioids are commonly used for treatment of many types of pain, including postoperative chronic and cancer pain. Respiratory depression is a potentially fatal adverse effect of opioids and is responsible for the present epidemic of opioid overdose deaths. Variability in response to opioids results in inadequate analgesia and untoward effects in some individuals. This is explained to some extent by genetic variations, gene-gene and drug-drug interactions.Areas covered: A literature review of the role of genetics in opioid induced respiratory depression (OIRD) was performed. Genetic variants alter opioid pharmacokinetics and pharmacodynamics, leading to increased blood (brain) concentrations of opioids, or altered efficacy, increasing the likelihood of OIRD. We report by gene and opioid, the clinical consequences of variations in genes involved in hepatic biotransformation, opioid sensitivity, blood brain barrier transport, and interactions with related systems (cannabinoids).Expert commentary: Although opioids have been the mainstay of analgesia for many centuries, the unravelling of the human genome is providing newer perspectives on genetic susceptibility to opioid adverse effects. It is anticipated that in the foreseeable future, individualized analgesia will become a reality wherein OIRD risk prediction algorithms will be incorporated to provide safer and more effective analgesia.
No takes yet. Share an insight, caveat, or question.
Chidambaran et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: